2-十四烷基棕榈酸 | 66880-77-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-十四烷基棕榈酸
• 英文名称: 2-tetradecylhexadecanoic acid
• 英文别名: 2-(tetradecyl)hexadecanoic acid；2-tetradecyl-hexadecanoic acid；2-Tetradecyl-hexadecansaeure；2-tetradecyl hexadecanoic acid
• CAS: 66880-77-1
• 化学式: C₃₀H₆₀O₂
• 分子量: 452.805
• InChiKey: ICSUXOJHXOJPOK-UHFFFAOYSA-N

物化性质

• 熔点：
  71-73°C
• 沸点：
  557.0±18.0 °C(Predicted)
• 密度：
  0.872±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、甲醇（微溶、加热）
• 稳定性/保质期：
  远离氧化物、光和热。

计算性质

• 辛醇/水分配系数(LogP)：
  14
• 重原子数：
  32
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-十四烷基棕榈酸 在 吡啶 、 4-二甲氨基吡啶 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 1,1,3,3-四甲基脲 、 锌 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 Benzyl 2-amino-6-O-benzyloxymethyl-2-deoxy-4-O-(diphenoxyphosphinyl)-3-O-(2-tetradecylhexadecanoyl)-β-D-glucopyranoside
  参考文献：
  名称：

  带有C-支链2-十四烷基十六烷酰基的一系列新的4-O-膦酰基-d-葡萄糖胺衍生物（脂质A亚基类似物）的合成

  摘要：

  摘要从苄基2-氨基开始合成了一系列带有3-O-连接或2-N-连接的C-支链2-十四烷基十六烷酰基的4-O-膦酰基-d-葡萄糖胺衍生物（脂质A亚基类似物）。 -2-脱氧-4，6-O-异亚丙基-β-d-吡喃葡萄糖苷和苄基2-氨基-6-O-苄氧基甲基-2-脱氧-4-O-（二苯氧基膦基）-β-d-吡喃葡萄糖苷。一些新化合物是巨噬细胞吞噬活性的有效诱导剂，并显示出对牛痘病毒的抗病毒活性。

  DOI：

  10.1016/0008-6215(91)80013-d
• 作为产物：
  描述：

  ditetradecylmalonic acid diethyl ester 在 potassium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 34.0h， 生成 2-十四烷基棕榈酸
  参考文献：
  名称：

  用于 π 共轭供体-受体半导体的双噻吩磺酰胺结构单元

  摘要：

  我们在此报告了基于新的 π 受体构建块双噻吩磺酰胺 (BTSA) 的 π 共轭小分子和聚合物。分子轨道计算和光学、电化学和晶体结构分析阐明了 BTSA 单元与其他受体构建块的结构和电子结构。场效应晶体管和光伏电池表明 BTSA 是构建 π 共轭半导体材料的有前途的单元。

  DOI：

  10.1021/jacs.6b03498

文献信息

• Synthesis of Sialyl Lewis X Ganglioside Analogs Containing A Variable Length Spacer Between the Sugar and Lipophilic Moieties
  作者：Keisuke Adachi、Yutaka Yamada、Hiroaki Wada、Akihiko Kameyama、Hideharu Ishida、Makoto Kiso

  DOI：10.1080/07328309808002340

  日期：1998.5.1

  Lew is X ganglioside analogs containing 4-(2-tetradecylhexadecanoylamino)benzyl group in place of ceramide and a variety of lengths of ethylene glycol chains as the spacer, have been synthesized. Glycosidation of O-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-glacto-2-nonulopyranosylonate)-(2→3)-O-(4-O-acetyl-2,6-di-O-benzoyl-β-D-galactopyranosyl)-(1→4)-O-[(2,3,4-tri-O-acet

  摘要合成了5个唾液酸Lew是X神经节苷脂类似物，它们含有4-（2-十四烷基十六烷酰氨基）苄基代替神经酰胺，并以各种长度的乙二醇链为间隔基。O-（5-乙酰氨基甲基-4,7,8,9-四-O-乙酰基-3,5-二脱氧-D-甘油-α-D-乳酸-2-壬基吡喃葡萄糖醛酸酯）-（2→3）的糖基化-O-（4-O-乙酰基-2,6-二-O-苯甲酰基-β-D-吡喃半乳糖基）-（1→4）-O-[（2,3,4-三-O-乙酰基α-L （fucopyranosyl）-（（1→3）]-2,4-di-O-benzoyl-α-D-glucopyranosyltrichloroacetimidate（13）与低聚乙二醇单苄基醚衍生物9、10、11和12，由相应的低聚乙二醇制得通过使用3-氟化硼醚化物进行4-硝基苄基化，还原并用2-十四烷基十六烷酸进行N-酰化，得到相应的糖脂衍生物14、15、16和17。
• Cyanoguanidine prodrugs
  申请人：——

  公开号：US20020165201A1

  公开（公告）日：2002-11-07

  The invention relates to compounds of the formula I 1 wherein X 1 and X 2 independently represent a bond; a straight, branched and/or cyclic hydrocarbon diradical, optionally substituted with one or more hydroxy, halogen, nitro, amino, cyano, aminosulfonyl, alkylsulfonylamino, alkylcarbonyl, formyl, aminocarbonyl or alkylcarbonylamino; a heteroarylene or non-aromatic heterocyclic hydrocarbon diradical, all of which are optionally substituted with one or more straight, branched and/or cyclic non-aromatic hydrocarbon radical, hydroxyl, halogen, amino, nitro, cyano, aminosulfonyl, alkylsulfonylamino, alkylcarbonyl, formyl, aminocarbonyl or alkylcarbonylamino; Y 1 and Y 2 independently represent a bond, an ether diradical (R′—O—R″), an amine diradical (R′—N—R″), O, S, S(O), S(O) 2 , C(O), NH—CO, CO—NH, SO 2 —N(R′), methylene or N(R′)—SO 2 wherein R′ and R″ independently represent straight or branched hydrocarbon diradicals containing up to 4 carbon atoms; Y 3 represents O, O—C(O), C(O)—O, N(R 8 ), R 8 being hydrogen or C 1-4 alkyl R 1 represents hydrogen or straight, branched and/or cyclic alkyl, optionally substituted with phenyl; or an aromatic hydrocarbon radical; R 2 represents aryl, heteroaryl or a non-aromatic heterocyclic hydrocarbon radical, all of which are optionally substituted; tetrahydropyranyloxy, di-(C 1-4 alkoxy)phosphinoyloxy or C 1-4 alkoxycarbonylamino; R 3 represents hydrogen; a straight, branched and/or cyclic hydrocarbon radical, optionally substituted with one or more amino, hydroxy, carboxy, halogen, nitro, cyano, alkoxy, aminocarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkoxycarbonylamino, sulfo, hydroxysulfonyloxy, dihydroxyphosphinoyloxy, phosphono, sulfamino, aminosulfonyl, aminoacylamino or dialkoxyphosphinoyl; heteroaryl or a non-aromatic heterocyclic hydrocarbon radical, all of which are optionally substituted with one or more straight, branched and/or cyclic hydrocarbon radical, amino, hydroxy, carboxy, halogen, nitro, cyano, alkoxy, aminocarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkoxycarbonylamino, sulfo, hydroxysulfonyloxy, dihydroxyphosphinoyloxy, phosphono, sulfamino, aminosulfonyl, aminoacylamino or dialkoxyphosphinoyl; 2 wherein s is an integer from 1 to 200; R 6 is hydrogen or an optionally substituted non-aromatic hydrocarbon radical; R 7 is independently hydrogen or methyl; R 4 and R 5 independently represent hydrogen; a straight, branched and/or cyclic hydrocarbon radical, optionally substituted with halogen, hydroxyl, halogen, amino, nitro or cyano; A represents hydrogen, an optionally substituted, straight, branched and/or cyclic hydrocarbon radical, hydroxy, halogen, nitro, cyano, heteroaryl, heteroaralkyl or thiol; m and r are independently integers from 0 to 4; and n is 0 or 1; Z − is a pharmaceutically acceptable anion, such as chloride, bromide, iodide, sulfate, methanesulfonate, p-toluenesulfonate, nitrate or phosphate. The compounds are well suited as prodrugs in human and veterinary therapy.

  该发明涉及以下式I的化合物： 其中X1和X2分别表示键；一种直链、支链和/或环烃二自由基，可选择地取代一个或多个羟基、卤素、硝基、氨基、氰基、氨基磺酰基、烷基磺酰胺基、烷基羰基、甲酰基、氨基羰基或烷基羰基氨基；一种杂芳烃基或非芳香杂环烃二自由基，均可选择地取代一个或多个直链、支链和/或环非芳香烃基、羟基、卤素、氨基、硝基、氰基、氨基磺酰基、烷基磺酰胺基、烷基羰基、甲酰基、氨基羰基或烷基羰基氨基； Y1和Y2分别表示键、醚二自由基（R′—O—R″）、胺二自由基（R′—N—R″）、O、S、S(O)、S(O)2、C(O)、NH—CO、CO—NH、SO2—N(R′)、亚甲基或N(R′)—SO2，其中R′和R″分别表示含有最多4个碳原子的直链或支链烃基； Y3表示O、O—C(O)、C(O)—O、N(R8)，其中R8为氢或C1-4烷基 R1表示氢或直链、支链和/或环烷基，可选择地取代苯基；或芳香烃基； R2表示芳基、杂芳基或非芳香杂环烃基，均可选择地取代；四氢吡喃氧基、二-(C1-4烷氧)磷酰氧基或C1-4烷氧羰基氨基； R3表示氢；一种直链、支链和/或环烃基，可选择地取代一个或多个氨基、羟基、羧基、卤素、硝基、氰基、烷氧基、氨基羰基、C1-4烷氧羰基、C1-4烷氧羰基氨基、磺酰基、羟基磺酰氧基、二羟基磷酰氧基、磷酸酯、磺胺基、氨基磺酰基、氨基酰氨基或二烷氧基磷酰基；杂芳基或非芳香杂环烃基，均可选择地取代一个或多个直链、支链和/或环烃基、氨基、羟基、羧基、卤素、硝基、氰基、烷氧基、氨基羰基、C1-4烷氧羰基、C1-4烷氧羰基氨基、磺酰基、羟基磺酰氧基、二羟基磷酰氧基、磷酸酯、磺胺基、氨基磺酰基、氨基酰氨基或二烷氧基磷酰基； 其中s为1至200的整数；R6为氢或可选择地取代的非芳香烃基；R7独立地为氢或甲基； R4和R5独立地表示氢；一种直链、支链和/或环烃基，可选择地取代卤素、羟基、卤素、氨基、硝基或氰基； A表示氢、可选择地取代的直链、支链和/或环烃基、羟基、卤素、硝基、氰基、杂芳基、杂芳基烷基或硫醇；m和r独立地为0至4的整数；n为0或1； Z-为药用可接受的阴离子，如氯化物、溴化物、碘化物、硫酸盐、甲磺酸盐、对甲苯磺酸盐、硝酸盐或磷酸盐。这些化合物非常适用于人类和兽医治疗中作为前药。
• [EN] NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA NEUROKININE 1
  申请人：LEO PHARMA AS

  公开号：WO2013124286A1

  公开（公告）日：2013-08-29

  The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C1-4 alkyl optionally substituted with hydroxy or NR8R9; R4 is hydrogen or oxo; R5 and R6 are independently hydrogen, hydroxy, NR8R9, C( =O)R7, C( =O)OR7, C( =O)NR8R9, C1-4 alkyl, wherein said C1-4 alkyl is optionally substituted with hydroxy, NR8R9 or a 5- or 6-membered heterocyclic ring, wherein said 5- or 6-membered heterocyclic ring is optionally substituted with C1-4 alkyl or C(=O)R7; or R5 and R6, together with the carbon atom to which they are attached, form =CH2 or a 5- or 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with C1-4 alkyl; R7 is hydrogen or C1-4 alkyl; R8 and R9 are independently hydrogen or C1-4 alkyl, or R8 and R9, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic ring, or a pharmaceutically acceptable salt or solvate thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating or ameliorating pruritic dermal diseases or conditions with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种根据公式（A）的化合物，其中n为1或2；R1和R2独立为氢，C1-4烷基，C1-4卤代烷基，C1-4烷氧基，CD3或卤素；R3为氢，C(=O)OR7或C1-4烷基，可选地被羟基或NR8R9取代；R4为氢或氧代；R5和R6独立为氢，羟基，NR8R9，C(=O)R7，C(=O)OR7，C(=O)NR8R9，C1-4烷基，其中所述C1-4烷基可选地被羟基，NR8R9或5-或6-成员的杂环环取代，其中所述5-或6-成员的杂环环可选地被C1-4烷基或C(=O)R7取代；或R5和R6与它们所连接的碳原子一起形成=CH2或5-或6-成员的杂环烷基，其中所述杂环烷基可选地被C1-4烷基取代；R7为氢或C1-4烷基；R8和R9独立为氢或C1-4烷基，或R8和R9与它们所连接的氮原子一起形成一个5-或6-成员的杂环环，或其药用可接受的盐或溶剂化物。本发明进一步涉及用于制备所述化合物的中间体，所述化合物用于治疗，包含所述化合物的药物组合物，使用所述化合物治疗或改善瘙痒性皮肤病或状况的方法，以及所述化合物在药物制造中的用途。
• Sulfur containing compounds
  申请人：——

  公开号：US20030220524A1

  公开（公告）日：2003-11-27

  This invention is directed to novel and known stufur containing compounds and pharmaceutically acceptable salts thereof that have utility as antifungals and as antiproliferative agents against mammalian cells, in particular cancer cells and most particularly leukemia-derived cells. The invention provides a method for synthesizing certain of the sulfur containing compounds that is more efficient than previously known methods.

  这项发明涉及新颖且已知的含有硫的化合物以及具有抗真菌活性和作为哺乳动物细胞，特别是癌细胞，尤其是白血病来源细胞的抗增殖剂的药用可接受盐。发明提供了一种合成某些含硫化合物的方法，该方法比先前已知的方法更有效。
• LIPOPOLYAMINES OF SPERMINE TYPE FOR CONSTRUCTION OF LIPOSOMAL TRANSFECTION SYSTEMS
  申请人：USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.

  公开号：US20150018436A1

  公开（公告）日：2015-01-15

  The invention provides new lipopolyamines of spermine type of the general formula I, wherein X is C—N bond or aminopolyethyleneglycolcarboxamide linker or o-hydroxy-alkylcarboxamide linker or ω-hydroxyalkylcarboxamidopolyethyleneglycol-carboxamide linker, and wherein a hydrophobic domain Y is an acyl symmetrically branched in the position C(2) or cholesteryl. The invention further provides a method of preparation of said lipopolyamines and their use for construction of polycationic liposomal drug carriers.

  该发明提供了一种新的通式I的脂质聚胺，其中X是C—N键或氨基聚乙二醇羧酰胺连接物或o-羟基烷基羧酰胺连接物或ω-羟基烷基羧酰胺聚乙二醇羧酰胺连接物，其中疏水域Y是在位置C(2)处对称分支的酰基或胆固醇。该发明还提供了所述脂质聚胺的制备方法及其用于构建多阳离子脂质体药物载体的用途。